Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

FOPO nets $94mm for Cadence Pharmaceuticals

Executive Summary

Cadence Pharmaceuticals Inc. (drugs for hospitalized patients) has netted $94mm through the follow-on public offering of 12.5mm common shares at $8 each (including the overallotment). The company will use some of the proceeds to market Ofirmev, which was approved this month for mild-to-severe pain in people who cannot take oral medications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies